Literature DB >> 10665784

Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy: a report of a randomised controlled trial.

S Dische1, M I Saunders, R Sealy, I D Werner, N Verma, C Foy, S M Bentzen.   

Abstract

BACKGROUND AND
PURPOSE: A randomised controlled trial of hyperbaric oxygen in the radiotherapy of Stage IIb and III carcinoma of cervix was performed between 1971 and 1980. Apart from an abstract giving an interim report in 1977, results have not been published.
MATERIAL AND METHODS: In a four arm study, 335 patients were randomised to treatment in 10 or 28 fractions, in hyperbaric oxygen or in air. Data is available concerning 327 cases and this has been analysed.
RESULTS: There was no advantage in tumour control shown with the use of hyperbaric oxygen. There was evidence for an increase in late radiation morbidity when treatment was given in hyperbaric oxygen rather than in air and when, using 10 fractions, a total dose of 45 rather than 40 Gy was achieved. For late intestinal morbidity, the fractionation sensitivity (alpha/beta ratio) was calculated to be 4.3 Gy and the steepness of the dose response curve (gamma50) to be 2.6.
CONCLUSIONS: Hyperbaric oxygen gave no benefit in the treatment of patients with stage IIb and III carcinoma of the cervix treated with radiotherapy using two fractionation regimes. Important data regarding late radiation morbidity has been revealed.

Entities:  

Mesh:

Year:  1999        PMID: 10665784     DOI: 10.1016/s0167-8140(99)00124-3

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system.

Authors:  Stefan A Carp; Amir Y Sajjadi; Christy M Wanyo; Qianqian Fang; Michelle C Specht; Lidia Schapira; Beverly Moy; Aditya Bardia; David A Boas; Steven J Isakoff
Journal:  Biomed Opt Express       Date:  2013-11-22       Impact factor: 3.732

2.  Inspired gas-induced vascular change in tumors with magnetic-resonance-guided near-infrared imaging: human breast pilot study.

Authors:  Colin M Carpenter; Rebecca Rakow-Penner; Shudong Jiang; Bruce L Daniel; Brian W Pogue; Gary H Glover; Keith D Paulsen
Journal:  J Biomed Opt       Date:  2010 May-Jun       Impact factor: 3.170

Review 3.  Hyperbaric oxygen therapy for malignancy: a review.

Authors:  Jurstine Daruwalla; Chris Christophi
Journal:  World J Surg       Date:  2006-12       Impact factor: 3.352

Review 4.  Hyperbaric oxygenation for tumour sensitisation to radiotherapy.

Authors:  Michael H Bennett; John Feldmeier; Robert Smee; Christopher Milross
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 5.  Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers.

Authors:  Theresa A Lawrie; John T Green; Mark Beresford; Linda Wedlake; Sorrel Burden; Susan E Davidson; Simon Lal; Caroline C Henson; H Jervoise N Andreyev
Journal:  Cochrane Database Syst Rev       Date:  2018-01-23

6.  Modelling duodenum radiotherapy toxicity using cohort dose-volume-histogram data.

Authors:  Daniel L P Holyoake; Marianne Aznar; Somnath Mukherjee; Mike Partridge; Maria A Hawkins
Journal:  Radiother Oncol       Date:  2017-06-06       Impact factor: 6.280

Review 7.  Hyperbaric oxygenation for tumour sensitisation to radiotherapy.

Authors:  Michael H Bennett; John Feldmeier; Robert Smee; Christopher Milross
Journal:  Cochrane Database Syst Rev       Date:  2018-04-11

Review 8.  Late gastrointestinal tissue effects after hypofractionated radiation therapy of the pancreas.

Authors:  Adnan Elhammali; Mukund Patel; Benjamin Weinberg; Vivek Verma; Jingxia Liu; Jeffrey R Olsen; Hiram A Gay
Journal:  Radiat Oncol       Date:  2015-09-04       Impact factor: 3.481

9.  Hyperfractionated abdominal reirradiation for gastrointestinal malignancies.

Authors:  Andrew Hunt; Prajnan Das; Bruce D Minsky; Eugene J Koay; Sunil Krishnan; Joseph M Herman; Cullen Taniguchi; Albert Koong; Grace L Smith; Emma B Holliday
Journal:  Radiat Oncol       Date:  2018-08-07       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.